文献速递腹部泌尿生殖CT

肾上腺偶发瘤与死亡风险的关系

The relationship between adrenal incidentalomas and mortality risk.
PubMed 文献 · Eur Radiol · 2019-04-16

该回顾性队列研究纳入2005至2009年间急诊就诊24小时内行腹部CT的成人,比较969例肾上腺偶发瘤患者与2907例无结节对照的死亡风险,中位随访8.9年。结果显示偶发瘤组全因死亡率显著升高(36.4% vs 31.6%,aHR 1.14,95%CI 1.003-1.29),探索性分析提示偶发瘤与恶性肿瘤、糖尿病、心衰等慢性疾病风险增加相关。

要点

  • 肾上腺偶发瘤与全因死亡率升高相关(aHR 1.14,95%CI 1.003-1.29)。
  • 肾上腺偶发瘤大小不能预测死亡率。
  • 探索性分析显示偶发瘤与恶性肿瘤、糖尿病、心衰等风险增加相关。

核心结论

  • 肾上腺偶发瘤与死亡率升高相关,可能是有临床价值的生物标志物。

研究设计与样本

  • 回顾性队列研究,纳入2005年1月1日至2009年12月31日某学术医学中心急诊就诊24小时内行腹部CT的成人,排除肾上腺疾病史、肾上腺实验室检查或癌症者,按年龄±1岁和检查日期±3个月以3:1匹配无结节对照,共969例偶发瘤和2907例对照进入生存分析。

诊断标准与关键数值

  • 全因死亡率:偶发瘤组353/969(36.4%) vs 无结节对照组919/2907(31.6%),死亡率差异7.6/1000人年,多变量校正风险比aHR 1.14(95%CI 1.003-1.29)。
  • 探索性分析:恶性肿瘤aHR 1.61(95%CI 1.22-2.12),糖尿病aHR 1.43(95%CI 1.18-1.71),心力衰竭aHR 1.32(95%CI 1.07-1.63),外周血管疾病aHR 1.28(95%CI 1.95-1.56),肾脏疾病aHR 1.21(95%CI 1.01-1.44),慢性肺部疾病aHR 1.22(95%CI 1.01-1.46)。

临床应用与阅片要点

  • 腹部CT发现肾上腺偶发瘤时,可提示其与死亡率升高相关,但偶发瘤大小不能预测死亡率。
  • 原文未据此给出推荐。

局限性

  • 探索性分析受缺失协变量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine all-cause mortality risk in patients with and without adrenal incidentaloma.

METHODS: Retrospective cohort study of patients with CT abdomen performed within 24 h of emergency room presentation at an academic medical center from January 1, 2005, to December 31, 2009, without history of adrenal disease, adrenal lab testing, or cancer. Incidentaloma cohort identified by database query of imaging reports followed by manual review and matched to no-nodule controls at 3:1 on age ± 1 year and exam date ± 3 months. Mortality ascertained by in-hospital deaths and National Death Index query. Survival analysis performed with Kaplan-Meier curves and Cox proportional hazards models.

RESULTS: Among 42,575 adults with abdominal CT exams, 969 adrenal incidentaloma patients and 2907 no-nodule controls were identified. All 3876 individuals entered survival analysis with 31,182 person-years at risk (median follow-up 8.9 years [IQR, 6.9-10.7]). All-cause mortality was significantly higher among those with adrenal incidentalomas (353/969, 36.4%) compared with those without (919/2907, 31.6%; mortality difference 7.6 per 1000 person-years; multivariable-adjusted hazard ratio [aHR] 1.14; 95% CI, 1.003-1.29). Exploratory analyses, limited by missing covariates, found that adrenal incidentalomas were associated with significantly increased incidence of malignancy (aHR 1.61; 95% CI, 1.22-2.12), diabetes (aHR 1.43; 95% CI, 1.18-1.71), heart failure (aHR 1.32; 95% CI, 1.07-1.63), peripheral vascular disease (aHR 1.28; 95% CI, 1.95-1.56), renal disease (aHR 1.21; 95% CI, 1.01-1.44), and chronic pulmonary disease (aHR 1.22; 95% CI, 1.01-1.46) compared with controls.

CONCLUSIONS: Adrenal incidentalomas are associated with increased mortality and may represent a clinically valuable biomarker.

KEY POINTS: • Adrenal incidentalomas are associated with increased mortality. • Adrenal incidentaloma size is not predictive of mortality. • On exploratory analyses, adrenal incidentalomas are associated with chronic illnesses.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Taya M, Paroder V, Bellin E, et al. The relationship between adrenal incidentalomas and mortality risk. Eur Radiol. 2019. PMID: 30993434. doi:10.1007/s00330-019-06202-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。